1. The DOSE trial (Diuretic Optimization Strategies Evaluation, 2011) used a 2×2 factorial design comparing high-dose versus low-dose IV furosemide strategies in acute decompensated heart failure. A 66-year-old woman taking oral furosemide 80 mg twice daily at home is admitted with decompensated HFrEF. She is assigned to the high-dose arm. At 72 hours, which of the following best describes what the DOSE trial demonstrated about high-dose diuresis compared to low-dose diuresis in terms of decongestion, symptom relief, and renal outcomes?

• A) High-dose diuresis produced significantly greater decongestion and significantly lower rates of all-cause mortality and HF rehospitalization at 60 days compared to low-dose diuresis; the modest creatinine increase in the high-dose arm was offset by the reduction in rehospitalization, establishing high-dose diuresis as the guideline-mandated first-line strategy for all patients admitted with acute decompensated heart failure regardless of baseline renal function
• B) High-dose diuresis produced greater decongestion and greater symptomatic improvement at 72 hours compared to low-dose diuresis, with a modest but non-significant increase in creatinine that did not translate into worse 60-day clinical outcomes; there was no significant difference between continuous infusion and intermittent bolus dosing, making high-dose bolus the favored approach in current practice
• C) High-dose diuresis produced greater decongestion at 72 hours but was associated with a statistically significant increase in 60-day mortality compared to low-dose diuresis; the trial was stopped early by the data safety monitoring board after the mortality signal emerged, and current AHA/ACC/HFSA guidelines recommend against high-dose strategies in patients with baseline creatinine above 1.5 mg/dL
• D) High-dose and low-dose diuresis produced equivalent decongestion at 72 hours, with no significant difference in weight loss, dyspnea scores, or physician-assessed fluid status; the trial's primary finding was that continuous infusion was significantly superior to bolus dosing for both decongestion and renal preservation, which is the basis for current guideline preference for continuous infusion in acute decompensated heart failure
• E) High-dose diuresis produced superior decongestion at 72 hours and significantly reduced 60-day all-cause mortality compared to low-dose diuresis (hazard ratio 0.74; p=0.03), but was associated with a 3-fold increase in dialysis-requiring acute kidney injury; current guidelines recommend high-dose strategies only in patients with baseline eGFR above 45 mL/min/1.73m² to avoid this renal complication

2. A 74-year-old man with HFrEF and stage 4 CKD (chronic kidney disease; eGFR 22 mL/min/1.73m²) is admitted with acute decompensation. Despite receiving IV furosemide 200 mg twice daily, urine output remains inadequate. His nephrologist notes that CKD-related accumulation of organic acids is contributing to the diuretic resistance. Which of the following best explains this mechanism and its clinical implication?

• A) Accumulated organic acids in CKD competitively inhibit NKCC2 in the thick ascending limb, directly reducing the number of transporter sites available for furosemide binding; the clinical implication is that higher doses of furosemide cannot overcome this competitive inhibition, and switching to a non-NKCC2 mechanism (acetazolamide) is the only effective strategy for diuretic resistance in advanced CKD
• B) Accumulated organic acids in CKD inhibit hepatic CYP3A4-mediated furosemide metabolism, causing paradoxical drug accumulation; the resulting suprapherapeutic plasma furosemide concentrations saturate organic acid transporters bidirectionally and impair net tubular secretion by reversing the concentration gradient that normally drives luminal delivery
• C) Accumulated organic acids in CKD bind to furosemide's sulfonamide side chain in the plasma, forming inactive furosemide-organic acid adducts that are not recognized by renal tubular organic acid transporters; the clinical implication is that a larger administered dose is required to generate sufficient free furosemide for tubular secretion
• D) Furosemide is secreted into the tubular lumen via organic acid transporters (OAT1 and OAT3) in the proximal tubule; in CKD, accumulated endogenous organic acids (including uremic solutes such as hippurate and indoxyl sulfate) compete with furosemide for these same transporters, reducing tubular secretion of furosemide and lowering luminal drug concentrations below those needed to saturate NKCC2 — this is a primary mechanism of diuretic resistance in CKD
• E) In CKD, reduced GFR (glomerular filtration rate) causes furosemide to be filtered more slowly across the glomerulus; because furosemide reaches the tubular lumen primarily by filtration rather than secretion, reduced GFR directly reduces the luminal drug concentration in proportion to the fall in eGFR, accounting for the diuretic resistance observed in advanced CKD

3. A 71-year-old man with HFrEF (LVEF 25%) and chronic diuretic resistance is admitted for worsening fluid overload. His cardiac output is severely reduced (estimated by clinical signs: cool extremities, narrow pulse pressure, elevated JVP [jugular venous pressure]). His team determines that low cardiac output is contributing to his diuretic resistance through reduced renal perfusion. Which of the following best explains this mechanism and the appropriate initial therapeutic response?

• A) Low cardiac output reduces renal blood flow and renal perfusion pressure, impairing delivery of furosemide to the proximal tubular OAT1/OAT3 (organic anion transporter 1/3) secretion sites; simultaneously, reduced GFR decreases tubular fluid flow past the thick ascending limb, lowering the contact time between luminal furosemide and NKCC2; the rational response is to optimize cardiac output through guideline-directed adjustment of GDMT (guideline-directed medical therapy) — including assessment of the adequacy of neurohormonal blockade — before escalating diuretic dose further
• B) Low cardiac output activates the sympathetic nervous system, producing renal afferent arteriolar constriction that raises intraglomerular pressure and paradoxically increases GFR; the resulting high-pressure filtration delivers excess fluid to the loop of Henle, overwhelming NKCC2 reabsorptive capacity; the rational response is beta-blockade intensification to reduce sympathetic drive and restore normal intraglomerular pressure regulation
• C) Low cardiac output reduces hepatic blood flow, impairing first-pass furosemide metabolism; the resulting higher systemic furosemide concentrations paradoxically suppress OAT1-mediated tubular secretion through a hepatorenal feedback loop; the rational response is switching to bumetanide, which does not undergo hepatic first-pass metabolism and therefore bypasses this feedback mechanism
• D) Low cardiac output directly inhibits NKCC2 transporter activity through reduced delivery of oxygen to thick ascending limb epithelial cells; cellular hypoxia in the TAL (thick ascending limb) reduces ATP availability for the basolateral Na-K-ATPase that maintains the electrochemical gradient necessary for NKCC2-mediated sodium cotransport; diuretics cannot restore NKCC2 function until myocardial oxygen delivery is normalized
• E) Low cardiac output reduces furosemide absorption from the peritoneal cavity in patients with ascites; in HFrEF with low output, peritoneal edema impairs the lymphatic drainage that normally transfers absorbed furosemide from the gut into the systemic circulation; switching to bumetanide, which is absorbed via the portal rather than lymphatic system, bypasses this mechanism

4. A patient with HFrEF and diuretic resistance is started on metolazone 5 mg daily added to IV furosemide 120 mg twice daily for sequential nephron blockade. Twelve hours after the first metolazone dose, nursing reports that the patient's urine output has increased dramatically to 400 mL/hour. Which of the following best identifies the primary electrolyte complication requiring immediate attention and explains the mechanism driving it?

• A) The primary risk is hyperkalemia: metolazone blocks NCC (Na-Cl cotransporter) in the distal convoluted tubule, increasing sodium delivery to the collecting duct where aldosterone-driven Na-K exchange dramatically amplifies potassium reabsorption; the combination of loop diuretic and metolazone creates a potassium-retaining state requiring reduction of any concurrent MRA (mineralocorticoid receptor antagonist) dose
• B) The primary risk is hypernatremia: the massive free-water loss from combined loop diuretic and thiazide-like diuretic action concentrates serum sodium by reducing tubular water reabsorption at both the loop and distal sites simultaneously; metolazone specifically inhibits aquaporin-2 insertion in the distal nephron, exacerbating free-water loss independent of sodium excretion
• C) The primary risk is severe hypokalemia with concurrent hypomagnesemia and potential hyponatremia: loop diuretics increase distal sodium delivery driving collecting duct potassium wasting, while metolazone's NCC blockade further amplifies this distal sodium load; the combination produces dramatically greater potassium and magnesium losses than either drug alone, and hypomagnesemia perpetuates hypokalemia by impairing renal potassium conservation — requiring urgent electrolyte assessment and likely aggressive replacement
• D) The primary risk is metabolic acidosis: metolazone inhibits carbonic anhydrase in the distal tubule, reducing bicarbonate reabsorption and generating a hyperchloremic non-anion gap metabolic acidosis; when combined with furosemide-induced volume contraction, this produces a mixed metabolic acidosis that requires sodium bicarbonate supplementation
• E) The primary risk is hypercalcemia: furosemide increases urinary calcium excretion but metolazone blocks the calcium excretion mechanism in the distal convoluted tubule, creating a net calcium-retaining state; the combination causes rapid calcium reaccumulation in patients with underlying hyperparathyroidism and requires immediate calcium level monitoring and calcitonin administration

5. A cardiologist is reviewing GDMT optimization for a 68-year-old woman with HFrEF (LVEF 32%, NYHA class II) on sacubitril/valsartan and carvedilol. She has not yet been started on an MRA. Her current laboratory values: serum potassium 5.1 mEq/L, creatinine 1.8 mg/dL (eGFR 34 mL/min/1.73m²). Which of the following best characterizes the appropriate approach to MRA initiation in this patient?

• A) MRA therapy is absolutely contraindicated because her eGFR of 34 mL/min/1.73m² falls below the 45 mL/min/1.73m² minimum threshold specified in AHA/ACC/HFSA 2022 guidelines; MRA initiation below this threshold is associated with unacceptable rates of fatal hyperkalemia regardless of baseline potassium, and her physician should document the contraindication and defer MRA therapy until eGFR improves with GDMT optimization
• B) MRA therapy can be initiated immediately at spironolactone 50 mg daily because her potassium of 5.1 mEq/L and eGFR of 34 mL/min/1.73m² are both within the ranges that RALES and EMPHASIS-HF investigators used for enrollment; starting at the target dose rather than a low starting dose maximizes the anti-fibrotic benefit of full MR blockade from the outset of therapy
• C) MRA therapy should be initiated with eplerenone rather than spironolactone at any eGFR below 45 mL/min/1.73m² because eplerenone is renally cleared and achieves lower peak plasma concentrations than spironolactone in CKD, reducing the risk of hyperkalemia; spironolactone's active metabolites accumulate to toxic concentrations at eGFR below 45 mL/min/1.73m² and are not cleared by dose reduction alone
• D) MRA therapy is appropriate in this patient and should be initiated at spironolactone 25 mg daily or eplerenone 25 mg daily with close monitoring; however, the combination of eGFR 34 mL/min/1.73m² and potassium 5.1 mEq/L places her at sufficiently elevated hyperkalemia risk that a new potassium binder (patiromer or sodium zirconium cyclosilicate) should be initiated simultaneously with the MRA to prevent hyperkalemia from the first dose
• E) MRA initiation requires careful individual risk-benefit assessment at this eGFR and potassium level: AHA/ACC/HFSA guidelines generally recommend against MRA initiation when potassium exceeds 5.0 mEq/L or eGFR is below 30 mL/min/1.73m², but this patient's eGFR of 34 mL/min/1.73m² and potassium of 5.1 mEq/L place her in a borderline zone where initiation at the lowest available dose (spironolactone 12.5–25 mg or eplerenone 25 mg) with repeat potassium and creatinine within 1 week is a reasonable guideline-consistent approach requiring shared decision-making

6. The RALES trial reported a hyperkalemia rate (K⁺ above 5.5 mEq/L) of only 2% in the spironolactone group. However, post-marketing surveillance after widespread adoption of spironolactone following RALES publication revealed substantially higher rates of hyperkalemia and hyperkalemia-related hospitalizations and deaths in real-world HF populations. Which of the following best explains this discrepancy?

• A) The RALES investigators used a different definition of hyperkalemia than post-marketing surveillance programs; RALES defined hyperkalemia as K⁺ above 6.0 mEq/L (not 5.5 mEq/L), producing an artificially low reported rate; post-marketing programs using the 5.5 mEq/L threshold revealed the true incidence, which was always 8–10% in the trial population as well
• B) RALES enrolled a highly selected trial population with favorable baseline renal function and potassium levels; most patients were not on ACE inhibitors at doses associated with significant RAAS suppression; post-marketing, spironolactone was applied broadly to older, sicker patients with more prevalent CKD, higher baseline potassium, concomitant RAAS inhibitor therapy, and less rigorous laboratory monitoring — all of which dramatically increase the risk of clinically significant hyperkalemia
• C) The RALES investigators excluded all patients with baseline creatinine above 1.0 mg/dL and baseline potassium above 4.0 mEq/L, restricting enrollment to patients with near-normal renal function and low-normal potassium; this extreme exclusion criterion produced a trial cohort so unrepresentative of real-world HF patients that the 2% hyperkalemia rate has no clinical relevance for prescribing decisions
• D) The discrepancy reflects publication bias: the RALES investigators selectively excluded hyperkalemia events that occurred within 30 days of dose titration from the primary safety analysis, classifying them as titration-related adverse events rather than treatment-emergent hyperkalemia; post-marketing surveillance captured all events regardless of timing, revealing the complete incidence
• E) Post-marketing surveillance reported a higher hyperkalemia rate because spironolactone formulation changed after RALES publication; the new commercial formulation uses a different excipient that increases bioavailability by approximately 40% compared to the formulation used in RALES, producing higher plasma concentrations and greater MR blockade than was studied in the trial

7. Before EMPHASIS-HF (2011), MRA use in HFrEF was largely confined to patients with NYHA class III–IV symptoms based on the RALES population. A 59-year-old man with HFrEF (LVEF 30%) reports mild exertional dyspnea climbing stairs but is comfortable at rest and at slow walking pace, consistent with NYHA class II. He is on optimized sacubitril/valsartan and carvedilol. His potassium is 4.2 mEq/L and eGFR is 58 mL/min/1.73m². Which of the following best describes how EMPHASIS-HF changed the evidence base for this patient and what current guidelines recommend?

• A) EMPHASIS-HF demonstrated that MRA therapy in NYHA class II HFrEF is beneficial only when LVEF is below 25%; above 25% LVEF, the anti-fibrotic benefit of MRA therapy is offset by the increased hyperkalemia risk in less severely ill patients, and AHA/ACC/HFSA guidelines give MRAs a class IIb recommendation in NYHA class II patients with LVEF between 25 and 35%
• B) EMPHASIS-HF demonstrated significant mortality and hospitalization reduction with eplerenone in NYHA class II HFrEF but only in patients not already receiving an ARB or ACE inhibitor; because this patient is on sacubitril/valsartan (which provides AT1 receptor blockade), the EMPHASIS-HF benefit cannot be extrapolated to him, and MRA is classified as class IIb in patients already on ARNI therapy
• C) EMPHASIS-HF demonstrated significant reduction in the composite of cardiovascular death and HF hospitalization with eplerenone in NYHA class II HFrEF on modern background GDMT; however, current AHA/ACC/HFSA guidelines restrict the class I MRA recommendation to patients with a recent HF hospitalization within the prior 12 months, because the EMPHASIS-HF enrollment criteria required either recent hospitalization or an elevated natriuretic peptide, and the benefit has not been confirmed in patients meeting only the natriuretic peptide criterion
• D) EMPHASIS-HF demonstrated a 37% relative reduction in cardiovascular death or HF hospitalization with eplerenone in patients with LVEF 35% or less and NYHA class II symptoms on optimized background GDMT including ACE inhibitor or ARB and beta-blocker; this directly expanded the evidence base from severe (NYHA III–IV) to mild HFrEF symptoms, and current AHA/ACC/HFSA guidelines give MRAs a class I recommendation in HFrEF with LVEF 35% or less regardless of whether symptoms are class II, III, or IV — provided eGFR and potassium are within acceptable thresholds
• E) EMPHASIS-HF demonstrated benefit only with eplerenone (not spironolactone) in NYHA class II HFrEF; because spironolactone was not studied in mild symptoms and its non-selective receptor profile produces greater endocrine side effects at the higher doses needed for full anti-fibrotic benefit in less symptomatic patients, AHA/ACC/HFSA guidelines specify eplerenone as the mandated MRA for NYHA class II and spironolactone as the mandated MRA for NYHA class III–IV based on the RALES and EMPHASIS-HF trial populations respectively

8. A 77-year-old woman with advanced HFrEF and concurrent cirrhosis has a serum albumin of 2.1 g/dL. She is receiving IV furosemide 160 mg twice daily with persistently inadequate urine output. Her physician considers hypoalbuminemia as a contributing mechanism of diuretic resistance. Which of the following best evaluates hypoalbuminemia as a mechanism of loop diuretic resistance in this patient and assesses its clinical significance in HF compared to nephrotic syndrome?

• A) Furosemide is greater than 95% protein-bound in the plasma; under normal conditions, it is the free fraction that is filtered and the protein-bound fraction that is actively secreted into the tubular lumen by OAT1/OAT3; hypoalbuminemia reduces the protein-bound fraction available for tubular secretion, lowering luminal furosemide concentrations and contributing to diuretic resistance; this mechanism is relevant in this patient given her severe hypoalbuminemia (2.1 g/dL), but it is clinically more significant in nephrotic syndrome than in isolated HF because nephrotic syndrome combines hypoalbuminemia with direct urinary albumin-furosemide complex losses that further reduce tubular drug delivery
• B) Furosemide is less than 10% protein-bound; hypoalbuminemia therefore has no pharmacokinetic effect on furosemide and does not contribute to diuretic resistance through any albumin-related mechanism; the resistance in this patient is entirely attributable to her cirrhosis-related portal hypertension altering renal arterial tone through hepatorenal reflex pathways
• C) Hypoalbuminemia reduces the oncotic pressure gradient across the tubular epithelium, causing furosemide to be reabsorbed from the tubular lumen back into the peritubular capillary before reaching NKCC2; this back-flux mechanism is proportional to the albumin deficit and is the dominant cause of diuretic resistance in any patient with serum albumin below 2.5 g/dL, regardless of the underlying cause of hypoalbuminemia
• D) The clinical solution to hypoalbuminemia-driven diuretic resistance is co-administration of IV albumin with IV furosemide; albumin binds furosemide in the plasma, creating an albumin-furosemide complex that is actively secreted into the tubular lumen at a rate 3-fold greater than free furosemide; randomized controlled trials have confirmed that IV albumin plus furosemide produces significantly greater diuresis than IV furosemide alone in all patients with serum albumin below 3.0 g/dL
• E) Hypoalbuminemia causes diuretic resistance by reducing the volume of distribution of furosemide to near zero, trapping the drug in the intravascular compartment and preventing its distribution to renal tissue; the reduced tissue concentration impairs the binding of furosemide to NKCC2 from the basolateral side of the thick ascending limb where its secondary tissue-level action occurs

9. Based on the ADVOR trial design and results, a hospitalist is considering whether to add acetazolamide to IV loop diuretic therapy in newly admitted patients with acute decompensated heart failure. Which of the following best describes the patient profile for whom the ADVOR evidence is most directly applicable and the mechanism that justifies adding acetazolamide to loop diuretic therapy?

• A) The ADVOR evidence is most applicable to patients with chronic diuretic resistance and evidence of the braking phenomenon; acetazolamide's primary benefit in ADVOR was in patients with more than 6 months of loop diuretic therapy, in whom it reversed the compensatory distal tubule NCC upregulation by inhibiting the WNK-SPAK kinase pathway that drives NCC phosphorylation and insertion into the apical membrane
• B) The ADVOR evidence is most applicable to patients with concurrent CKD and eGFR below 30 mL/min/1.73m², in whom acetazolamide's proximal tubule action is particularly potent because accumulating uremic organic acids paradoxically enhance carbonic anhydrase activity in the proximal tubule, making NKCC2-dependent reabsorption more resistant to loop diuretics and acetazolamide blockade more effective at restoring sodium delivery distally
• C) The ADVOR evidence is most applicable to patients admitted with acute decompensated HF with clinical signs of volume overload who are receiving standardized background IV loop diuretic therapy; acetazolamide inhibits carbonic anhydrase in the proximal tubule, reducing bicarbonate-coupled sodium reabsorption and delivering additional sodium to the loop of Henle — complementing NKCC2 blockade by loop diuretics through a mechanistically distinct proximal site of action, producing greater net natriuresis than loop diuretic alone
• D) The ADVOR evidence is most applicable to patients with HFpEF (heart failure with preserved ejection fraction; LVEF above 50%) and diuretic resistance because the ADVOR trial enrolled exclusively HFpEF patients; acetazolamide's mechanism in this population involves inhibition of carbonic anhydrase in the myocardium, reducing intracellular acidosis during ischemic episodes and improving diastolic function independent of its renal natriuretic effect
• E) The ADVOR evidence applies equally to all patients with acute decompensated heart failure regardless of symptom severity, diuretic history, or renal function because ADVOR enrolled a heterogeneous all-comers population and showed consistent benefit across all subgroups; the mechanism of benefit was shown in ADVOR to involve acetazolamide's natriuretic peptide-potentiating effect through inhibition of neprilysin in the proximal tubule, a mechanism distinct from carbonic anhydrase inhibition

10. A cardiologist is selecting between spironolactone and eplerenone for three different HFrEF patients: Patient 1, a 58-year-old man who developed gynecomastia and breast tenderness on spironolactone 25 mg; Patient 2, a 62-year-old woman with HFrEF and LVEF 28% who sustained an acute MI (myocardial infarction) 10 days ago and now has symptomatic HF; Patient 3, a 55-year-old premenopausal woman with HFrEF who developed amenorrhea on spironolactone. Which of the following best identifies in which patient(s) eplerenone is specifically preferred and explains why?

• A) Eplerenone is specifically preferred only in Patient 2 (post-MI LV dysfunction) because EPHESUS studied eplerenone, not spironolactone, in the post-MI setting; the specific cardioprotective mechanism of eplerenone in the post-MI myocardium — aldosterone-driven collagen cross-linking inhibition via MR blockade in ischemic scar tissue — has only been validated with eplerenone and cannot be extrapolated to spironolactone because spironolactone's androgen receptor binding impairs infarct healing through anti-androgenic suppression of cardiac fibroblast growth factor signaling
• B) Eplerenone is specifically preferred in all three patients: in Patients 1 and 3 because eplerenone's high MR selectivity eliminates the androgen receptor-mediated gynecomastia and progesterone receptor-mediated menstrual irregularities that are mechanism-based consequences of spironolactone's non-selectivity; in Patient 2 because EPHESUS specifically studied eplerenone in post-MI LV dysfunction with HF, establishing eplerenone as the evidence-based MRA for this indication
• C) Eplerenone is specifically preferred only in Patients 1 and 3 due to spironolactone's sex hormone receptor side effects; Patient 2 should receive spironolactone rather than eplerenone because spironolactone's additional anti-androgenic action provides cardioprotection in post-MI remodeling through suppression of androgen-driven cardiac fibroblast activation, which eplerenone's high MR selectivity cannot achieve
• D) Eplerenone is not specifically preferred in any of these patients because eplerenone has lower MR binding affinity than spironolactone and therefore requires doses (50 mg daily) that produce greater absolute MR blockade but equivalent endocrine side effects due to the dose-dependent increase in off-target receptor interactions at higher plasma concentrations; all three patients should receive reduced-dose spironolactone (12.5 mg daily) rather than switching to eplerenone
• E) Eplerenone is specifically preferred only in Patient 1 because gynecomastia is the only spironolactone side effect with a validated mechanistic basis for eplerenone substitution; Patient 3's amenorrhea is more likely caused by her HFrEF itself (through reduced LH and FSH secretion from low cardiac output states) rather than spironolactone's progesterone receptor binding, and eplerenone substitution would not be expected to restore normal menstrual cycles

11. During IV diuresis for acute decompensated HFrEF, a patient's creatinine rises from 1.1 to 1.6 mg/dL (0.5 mg/dL increase) over 48 hours. The clinical team must decide whether this represents acceptable WRF (worsening renal function) during effective decongestion or a signal of true renal ischemia requiring diuretic modification. Which of the following clinical findings would most strongly indicate that this represents true renal ischemia requiring a change in diuretic strategy rather than acceptable WRF?

• A) A urine sodium concentration below 20 mEq/L measured on a spot urine specimen, indicating that the distal nephron is responding appropriately to furosemide by maximizing sodium reabsorption in the collecting duct; this low urine sodium confirms effective GDMT-mediated neurohormonal activation and should prompt escalation of the furosemide dose rather than reduction
• B) Persistent elevation of BNP (B-type natriuretic peptide) above 500 pg/mL at 48 hours of IV diuresis, indicating that ventricular wall stress has not improved despite diuretic therapy; persistent BNP elevation combined with rising creatinine identifies patients who have reached the maximum benefit of diuretic therapy and for whom renal replacement therapy is the next appropriate step
• C) A net fluid removal of greater than 1.5 liters per day averaged over the 48-hour period, indicating that the diuresis rate exceeds the physiological rate of fluid mobilization from the interstitium into the intravascular compartment; at rates above 1.5 liters per day, all creatinine increases represent obligate ischemic AKI from intravascular volume depletion, and furosemide must be reduced to the lowest dose that maintains a net-even fluid balance
• D) Persistent elevation of jugular venous pressure (JVP) at 48 hours combined with the creatinine rise, indicating that the patient is still volume overloaded and the creatinine increase reflects the cardiorenal physiology of venous congestion impairing renal perfusion rather than over-diuresis; continued diuresis is appropriate and the creatinine rise in this context does not require furosemide reduction
• E) Signs of true intravascular volume depletion — including orthostatic hypotension, flat or collapsed JVP, dry mucous membranes, and oliguria with urine output less than 0.5 mL/kg/hour despite adequate diuretic dosing — indicating that the effective circulating volume has fallen below the level needed to sustain adequate renal perfusion pressure; these findings distinguish genuine renal ischemia from acceptable WRF and require reduction or temporary hold of diuresis with reassessment

12. A patient with HFrEF is maintained on furosemide 80 mg twice daily and spironolactone 25 mg daily with a stable serum potassium of 4.3 mEq/L. Over the next month, three clinical changes occur sequentially: (1) his furosemide dose is reduced from 80 mg twice daily to 40 mg once daily because he achieves near-euvolemia; (2) his creatinine rises from 1.2 to 1.9 mg/dL due to intercurrent dehydration from a gastrointestinal illness; (3) his cardiologist adds lisinopril 5 mg daily for additional RAAS blockade. After all three changes, his potassium is 5.8 mEq/L. Which of the following best explains how each of the three changes contributed to this potassium rise?

• A) All three changes produced potassium retention through identical mechanisms: each reduced GFR, and reduced GFR universally impairs potassium excretion at the distal tubule by reducing tubular flow rate below the threshold needed for flow-mediated potassium secretion; the 5.8 mEq/L potassium represents a predictable consequence of any three simultaneous GFR-reducing interventions regardless of their individual mechanisms
• B) Furosemide dose reduction increased potassium retention because lower furosemide doses increase GFR and intraglomerular pressure, triggering tubuloglomerular feedback that reduces potassium secretion in the distal tubule; creatinine rise impaired potassium excretion through metabolic acidosis-mediated transcellular shift of potassium out of cells; lisinopril added potassium retention by blocking ACE-independent aldosterone generation through chymase pathways in cardiac tissue
• C) Furosemide dose reduction worsened potassium retention through increased proximal tubular sodium reabsorption that reduced distal sodium delivery; creatinine rise caused potassium retention through direct tubular toxicity of accumulated creatinine metabolites on collecting duct principal cell Na-K-ATPase; lisinopril caused potassium retention through direct inhibition of the adrenal CYP11B2 (aldosterone synthase) enzyme responsible for aldosterone synthesis rather than through ACE inhibition
• D) Furosemide dose reduction removed a potassium-wasting force (reduced distal sodium delivery driving collecting duct Na-K exchange), allowing spironolactone's potassium-retaining effect to dominate; the creatinine rise from dehydration reflects reduced GFR, which directly reduces tubular potassium secretory capacity at the collecting duct; lisinopril's ACE inhibition reduces angiotensin II-stimulated aldosterone secretion, further reducing collecting duct potassium excretion — all three changes converged on reduced urinary potassium excretion in a patient already on MRA therapy
• E) All three changes produced potassium retention exclusively through extrarenal mechanisms: furosemide reduction increased aldosterone-mediated potassium uptake into skeletal muscle; the acute illness reduced glucagon secretion, removing glucagon-mediated transcellular potassium efflux from hepatocytes; lisinopril blocked the kinin-bradykinin system, reducing prostaglandin E2-mediated potassium secretion in the sweat glands

13. The TOPCAT trial has been described as one of the most methodologically controversial large HF trials in recent years. A cardiologist is counseling a 72-year-old woman with HFpEF (LVEF 58%, NYHA class II, prior HF hospitalization 4 months ago) regarding spironolactone therapy. Which of the following best explains the TOPCAT controversy and its implication for this clinical decision?

• A) The TOPCAT controversy centers on striking geographic heterogeneity in both event rates and pharmacological evidence of drug exposure: patients enrolled in Russia and Georgia had markedly lower event rates than patients from the Americas, and plasma concentrations of canrenone — a spironolactone metabolite used as an adherence biomarker — were near zero in the Russia/Georgia cohort, raising serious concern that patients in those regions did not actually receive active drug; when analyses are restricted to patients from the Americas, spironolactone shows a significant reduction in HF hospitalization, which informs the current class IIb guideline recommendation for MRAs in symptomatic HFpEF with prior hospitalization
• B) The TOPCAT controversy centers on the dose used: the trial used spironolactone 45 mg daily maximum, which is below the 50 mg daily minimum effective dose for anti-fibrotic MR blockade in cardiac tissue; the Americas subgroup showed benefit because those patients were more likely to receive dose escalation, whereas the Russia/Georgia subgroup received only the 15 mg starting dose; this dose heterogeneity fully explains the geographic difference and has no implications for trial validity
• C) The TOPCAT controversy centers on baseline characteristic imbalance: the Russia/Georgia patients were substantially younger and had lower LVEF than the Americas cohort, meaning the two geographic groups effectively studied different diseases; the Americas patients had true HFpEF while the Russia/Georgia patients had HFrEF misclassified as HFpEF, and the negative overall trial result reflects the dilution of a true HFpEF benefit by an HFrEF null effect in the same trial
• D) The TOPCAT controversy is fully resolved: a 2019 post-hoc re-analysis confirmed that the overall trial result (hazard ratio 0.89; p=0.14) represents the true effect of spironolactone in HFpEF after correcting for geographic enrollment bias using propensity score adjustment; the current class IIb recommendation is based on this corrected analysis and the overall trial result rather than on the Americas subgroup alone
• E) The TOPCAT controversy is clinically irrelevant because EMPEROR-Preserved and DELIVER subsequently demonstrated class I benefit for SGLT2 (sodium-glucose cotransporter 2) inhibitors in HFpEF; current AHA/ACC/HFSA guidelines have removed the MRA recommendation for HFpEF entirely, replacing it with a class I SGLT2 inhibitor recommendation, and spironolactone should not be prescribed for HFpEF in 2025 regardless of symptom severity or hospitalization history

14. The TRANSFORM-HF trial (2023) compared torsemide versus furosemide as maintenance loop diuretic therapy after hospitalization for heart failure. A cardiologist is deciding whether to discharge a patient on torsemide rather than furosemide based on TRANSFORM-HF. Which of the following best summarizes what TRANSFORM-HF demonstrated, what it did not demonstrate, and the most clinically defensible interpretation for prescribing decisions?

• A) TRANSFORM-HF demonstrated that torsemide significantly reduced all-cause mortality compared to furosemide (HR 0.79; p=0.02) and significantly reduced HF rehospitalization at 12 months (HR 0.81; p=0.03); based on these results, AHA/ACC/HFSA guidelines now give torsemide a class I recommendation over furosemide for post-hospitalization maintenance therapy in HFrEF, and furosemide should only be used when torsemide is unavailable or not tolerated
• B) TRANSFORM-HF found no significant difference in all-cause mortality (HR 1.02; p=0.82) or the composite of mortality and hospitalization (HR 0.92; p=0.26) between torsemide and furosemide; however, torsemide's pharmacokinetic advantages — higher and more consistent oral bioavailability (80–90% vs. 10–100% for furosemide), longer duration of action, and fewer diuretic-related side effects in some analyses — support a clinically defensible preference for torsemide in outpatient maintenance therapy, particularly in patients with prior furosemide absorption variability
• C) TRANSFORM-HF demonstrated that torsemide was non-inferior to furosemide for all-cause mortality but significantly superior for HF rehospitalization (HR 0.81; p=0.03); the trial established torsemide as the preferred agent for post-hospitalization patients specifically because the rehospitalization benefit was concentrated in patients with eGFR above 45 mL/min/1.73m², which is the population most likely to be discharged on loop diuretics in contemporary practice
• D) TRANSFORM-HF demonstrated that furosemide was superior to torsemide for decongestion speed (time to achieve dry weight) during the post-hospitalization period, while torsemide was superior for long-term LVEF preservation at 12 months; the trial therefore established furosemide as preferred for acute congestion and torsemide as preferred for structural remodeling prevention during outpatient maintenance
• E) TRANSFORM-HF was terminated early after 800 patients due to an unexpected finding that torsemide produced significantly higher rates of acute tubular necrosis than furosemide; the trial's data safety monitoring board concluded that torsemide's longer duration of action increased the cumulative duration of tubular drug exposure, producing greater NKCC2-mediated ischemia in the thick ascending limb than shorter-acting furosemide

15. A 69-year-old man with HFrEF is admitted with acute decompensation. Review of his medication list reveals he has been taking ibuprofen 400 mg three times daily for hip osteoarthritis for the past 3 weeks. Despite IV furosemide 120 mg twice daily, his urine output remains inadequate. Which of the following best explains how NSAIDs (non-steroidal anti-inflammatory drugs) produce diuretic resistance in this patient through two distinct but complementary mechanisms, and identifies the correct clinical response?

• A) NSAIDs cause diuretic resistance through direct competitive inhibition of OAT1 and OAT3 in the proximal tubule, blocking active secretion of furosemide into the tubular lumen; NSAIDs also directly block ENaC in the collecting duct, reducing the electrochemical driving force for sodium reabsorption that furosemide-induced distal sodium delivery depends upon; the clinical response is to switch to a non-OAT-competing loop diuretic such as ethacrynic acid, which does not require OAT1/OAT3 secretion and is not displaced by NSAIDs
• B) NSAIDs cause diuretic resistance by activating the renin-angiotensin-aldosterone system through COX-2 (cyclooxygenase 2)-dependent prostaglandin synthesis in the juxtaglomerular apparatus; prostaglandin I2 normally suppresses renin release, and NSAIDs remove this suppression, dramatically increasing aldosterone secretion and sodium retention in the collecting duct that overwhelms any diuretic effect; the clinical response is to add an MRA to overcome the NSAID-driven aldosterone surge
• C) NSAIDs inhibit prostaglandin synthesis by blocking COX (cyclooxygenase) enzymes, attenuating the early prostaglandin-mediated venodilatory component of IV furosemide action (reducing preload benefit) and impairing renal prostaglandin-mediated vasodilation, which reduces renal blood flow, decreases delivery of furosemide to the OAT1/OAT3 secretion site, and reduces GFR; the combination of these two mechanisms — blunting both the early hemodynamic benefit and the tubular delivery of furosemide — produces clinically significant diuretic resistance; the clinical response is to discontinue ibuprofen and substitute an NSAID-free analgesic such as acetaminophen
• D) NSAIDs produce diuretic resistance exclusively through sodium retention in the distal convoluted tubule: COX-1 inhibition in the distal tubule removes prostaglandin E2-mediated inhibition of NCC, dramatically upregulating thiazide-sensitive sodium reabsorption in a manner pharmacologically equivalent to the braking phenomenon; this mechanism is fully reversed by adding metolazone to block the NSAID-activated NCC, without requiring NSAID discontinuation
• E) NSAIDs cause diuretic resistance through two sequential mechanisms: first, COX-2 inhibition in the thick ascending limb directly potentiates NKCC2 activity by removing the prostaglandin E2-mediated inhibition of NKCC2 phosphorylation, making NKCC2 resistant to furosemide binding; second, accumulated arachidonic acid from COX blockade is shunted to the lipoxygenase pathway, producing leukotriene B4 that constricts the efferent arteriole and paradoxically increases GFR to supranormal levels, washing furosemide past NKCC2 before adequate drug-transporter binding occurs

16. A hospitalist is reviewing GDMT optimization across four patients with HFrEF (LVEF 30–35%, NYHA class II–III) and considering whether to initiate MRA therapy in each. Patient A: K⁺ 4.6 mEq/L, eGFR 52 mL/min/1.73m², on ACE inhibitor and carvedilol. Patient B: K⁺ 5.3 mEq/L, eGFR 38 mL/min/1.73m², on sacubitril/valsartan. Patient C: K⁺ 4.1 mEq/L, eGFR 28 mL/min/1.73m², on lisinopril. Patient D: K⁺ 4.4 mEq/L, eGFR 55 mL/min/1.73m², incidentally discovered bilateral renal artery stenosis on recent CT angiography, on ACE inhibitor. Which of the following best identifies the patient in whom MRA initiation is most clearly appropriate and the patient in whom it is most clearly contraindicated?

• A) Patient A is most clearly appropriate for MRA initiation; Patient D is most clearly contraindicated because bilateral renal artery stenosis is not itself an MRA contraindication, but the ACE inhibitor Patient D is taking must be discontinued before MRA initiation, and the combination of ACE inhibitor and MRA in the presence of bilateral renal artery stenosis produces a synergistic risk of ischemic nephropathy that requires ACE inhibitor withdrawal as the first step before any MRA decision
• B) Patient B is most clearly appropriate for MRA initiation because his HFrEF is most severe (indicated by sacubitril/valsartan use) and the MRA survival benefit is greatest in the most symptomatic patients; Patient C is most clearly contraindicated because eGFR 28 mL/min/1.73m² is below 30 mL/min/1.73m², placing him in the absolute contraindication zone for MRA initiation regardless of potassium
• C) Patient C is most clearly appropriate for MRA initiation because his potassium of 4.1 mEq/L provides the most margin before reaching the hyperkalemia threshold; Patient B is most clearly contraindicated because potassium above 5.0 mEq/L is a guideline-defined threshold at which MRA initiation is not recommended, and his concurrent eGFR of 38 mL/min/1.73m² compounds the hyperkalemia risk to an unacceptable level
• D) Patient D is most clearly appropriate for MRA initiation because his normal potassium and preserved eGFR represent the lowest hyperkalemia risk of the four patients; Patient A is most clearly contraindicated because ACE inhibitor therapy with concurrent MRA produces the highest-risk RAAS triple blockade when combined with a beta-blocker, and AHA/ACC/HFSA guidelines specify that MRAs may only be added to ARNI (not ACE inhibitor) as the RAAS backbone to avoid this triple blockade combination
• E) Patient A is most clearly appropriate for MRA initiation (acceptable potassium, eGFR well above 30 mL/min/1.73m², on guideline-recommended background GDMT); Patient C is most clearly contraindicated (eGFR 28 mL/min/1.73m² falls below the guideline threshold of 30 mL/min/1.73m² below which MRA initiation is not recommended due to unacceptable hyperkalemia and renal impairment risk); Patient B warrants individualized assessment given potassium above 5.0 mEq/L; Patient D warrants particular caution because bilateral renal artery stenosis renders the kidney dependent on angiotensin II-mediated efferent arteriolar tone to maintain GFR, and adding MRA to existing ACE inhibitor markedly increases the risk of acute renal failure from combined RAAS blockade in the setting of fixed renovascular disease